Neurol. praxi. 2009;10(5):310-313

Breakthrough pain - clinical presentation and treatment

MUDr. Dana Vondráčková
Centrum léčby bolesti FN Na Bulovce, Subkatedra léčby bolesti a akupunktury IPVZ, Praha

Breakthrough pain is one of the symptoms of tumorous pain. This term is not always used by physicians for the same symptom. The article presents

the latest exact definition of breakthrough pain and mentions the states that are considered to be breakthrough pain but do not correspond

to the current definition. Advanced stages of disease are a risk period for a progressive development of pain as well as breakthrough pain.

Pathophysiologically, all kinds of pain are involved in breakthrough pain: nociceptive, neuropathic, and mixed pain. The speed of onset

and duration of pain are essential data for breakthrough pain, which can range from several minutes to several hours and occur despite

a well adjusted treatment of basic pain. Breakthrough pain has to be diagnosed correctly and treated with respect to the basic pain

and the general condition of the patient. So far, treatment options have been limited to rapid-acting morphine that, however, lacks

the characteristics required for this type of pain. Fentanyl sublingual or buccal tablets or nasal spray come closest to an ideal drug for

treating breakthrough pain.

Keywords: breakthrough pain, opioids, transmucosal administration, nasal spray.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vondráčková D. Breakthrough pain - clinical presentation and treatment. Neurol. praxi. 2009;10(5):310-313.
Download citation

References

  1. Davies A, In: Davies A. (ed.) Cancer-related Breakthrough Pain. Oxford Pain Management Library: Oxford University Press 2006. Go to original source...
  2. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain charateristics and responses to treatment at VA medical center. Pain 2003; 101: 55-64. Go to original source... Go to PubMed...
  3. Portenoy RK, Hagen NA. Breakthrough pain: definition and characteristics. Pain 1990; 41: 273-281. Go to original source... Go to PubMed...
  4. Zeppetella G, O´Doherty CA. Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000; 20: 87-92. Go to original source... Go to PubMed...
  5. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, DeConno F. Episodic (breathrough) pain. Consensus conference of an Expert Working Group of the European Association for Palliative Care; Cancer 2002; 94: 832-839. Go to original source... Go to PubMed...
  6. Coyle N. In their own words: seven advanced cancer patients describe their experience with pain and the use of opioid drugs. J Pain Symptom Manage 2004; 27: 300-309. Go to original source... Go to PubMed...
  7. Ferrell BR, Juarez G, Borneman T. Use of routine and breakthrough analgesia in home care. Oncology Nursing Forum 1999; 26: 1655-1661.
  8. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews 2002; 2 CD 002068. Go to original source... Go to PubMed...
  9. Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Cassuccio A. Safety and effectivness of intravenous morphine for episodic breakthough pain in patients receiving transderma buprenorphine; J Pain Symptom Manage 2006; 32: 175-179. Go to original source... Go to PubMed...
  10. Mercadante S, Arcuri E, Ferrera P, Villari P, Salvatore M. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom manage 2005; 30: 485-491. Go to original source... Go to PubMed...
  11. Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Cassuccio A. Safety and effectivness of intravenous morphine for episodic breakthough pain in patients receiving transderma buprenorphine. J Pain Symptom Manage 2006; 32: 175-179. Go to original source... Go to PubMed...
  12. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch M, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for treatment of breakthrough pain in canacer patients: a controlled dose titration study Pain 1999; 79: 303-312. Go to original source... Go to PubMed...
  13. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, Berris R, Busch MA, Nordbrook E, Loseth DB, Portenoy RK. Longterm safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22: 575-583. Go to original source... Go to PubMed...
  14. Enting RH, Mucchiano C, Oldenmenger WH, Fritzon M, Wallen A, Goslinda-van derGaag S, Sillevis Smitt PA, Delhaas E. The, ,Pain pen" for breakthrough pain: A promising treatment. J Pain Symptom Manage 2005; 29: 213-217. Go to original source... Go to PubMed...
  15. Slatkin NE, Xie Fang, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid - tolerant patients with cancer related chronic pain. J Support Oncol 2007; 5: 327-334. Go to PubMed...
  16. Lennernäs B, Hedner T, Holmeberg M, Bredenberg S, Nyström C, Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approch to treatment of incident pain. Br. J. Clin. Pharmacol 2004; 59, 2: 249-253. Go to original source... Go to PubMed...
  17. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat med. 2001; 15: 323-328. Go to original source... Go to PubMed...
  18. Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood brain barrier. Indian J. Pharmacol 2004; 36: 140-147.
  19. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000; 20: 253-258. Go to original source... Go to PubMed...
  20. Caraceni A, Portenoy RK. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-134. Go to original source... Go to PubMed...
  21. Zeppetella G, Ribeiro MDC. Pharmacotherapy of cancer - related episodic pain. Expert Opin Pharmacotherapy 2003; 4: 493-502. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.